Marginal Zone Lymphoma treatment market is projected at a significant CAGR of 6.05% during the forecast period (2021-2030), as per DelveInsight

Marginal Zone Lymphoma treatment market is projected at a significant CAGR of 6.05% during the forecast period (2021-2030), as per DelveInsight

PR Newswire

LAS VEGAS, Feb. 9, 2021

Increase in patient pool, expected entry of emerging therapies, and deeper penetration of these drugs in 7MM are key factors in driving Marginal Zone Lymphoma market 

LAS VEGAS, Feb. 9, 2021 /PRNewswire/ -- DelveInsight's "Marginal Zone Lymphoma (MZL) Market" report provides a complete comprehension of the Marginal Zone Lymphoma,  historical and forecasted epidemiology and the MZL market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Marginal Zone Lymphoma market report also proffers an analysis of recent MZL treatment practice/algorithm, market drivers, market barriers and unmet medical needs. 

DelveInsight_Logo

Some of the highlights of Marginal Zone Lymphoma Market Research Report

For additional information on Market Impact by Therapies, visit: Marginal Zone Lymphoma Market Forecast Analysis 

Marginal Zone B-cell lymphoma is a group of indolent Non-Hodgkin lymphoma (NHL) B-cell lymphomas that account for approximately 5‒17% of all NHL cases. The total Non-Hodgkin lymphoma incident population in the 7MM was estimated to be 174,941 in 2020. Out of these, the total Marginal Zone Lymphoma incident population in the 7MM was 22,268 in the same year. 

The Marginal Zone Lymphoma Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

Review a sample report for more insights @ Marginal Zone Lymphoma Market Insight 

Marginal Zone Lymphoma Treatment Market

Treatment selection for an MZL patient depends on the type, stage, and location of the disease. The total MZL market is categorized into three types based on the line of therapies, first-line, second-line, and third-line of therapies. The first line treatment comprises only the supportive therapies, including rituximab monotherapy, R-CHOP/R-CVP, rituximab plus bendamustine, cytotoxic chemotherapy, antiviral therapy for hepatitis C infection, Antibiotic/PPIs.

In May 2019, the FDA approved lenalidomide (Revlimid) combined with a rituximab product for previously treated follicular lymphoma (FL) and previously-treated MZL. Moreover, in December 2019, the European Commission approved Revlimid (lenalidomide) in combination with rituximab for the treatment of adult patients with previously treated MZL. The drug is not being approved in Japan but is expected to get launched in the forecast period 2020–2030 and hence is an emerging therapy for Japan.

Revlimid is an immune-modulating therapy with proven anti-myeloma effects. The drug is an oral therapy that was shown to work in 3 ways in animal models and in vitro, it aids the immune system to identify and eradicate myeloma cells. It targets and destroys myeloma cells and helps prevent new myeloma cell growth by starving them of blood. 

Several pharmaceutical key players have taken the initiatives to meet the unmet needs of the present situation of the MZL market. Some of the key players are in the late and mid clinical development stages with their leading drug candidates. MZL pipeline possesses potential drugs as monotherapies as well as combination therapies. 

Marginal Zone Lymphoma Emerging Therapies Along with Key Players 

And several others. 

Concluding thoughts on Marginal Zone Lymphoma Market Growth

Marginal Zone Lymphoma Market Drivers

Marginal Zone Lymphoma Market Barriers

Scope of the Marginal Zone Lymphoma Market Insight  

Request for a Webex demo of the report @ Marginal Zone Lymphoma Market Size 

Table of Contents 

1

Key Insights on Marginal Zone Lymphoma

2

Executive Summary of Marginal Zone Lymphoma

3

Marginal Zone Lymphoma Market Overview at a Glance

4

Disease Background and Overview: Marginal Zone Lymphoma

5

Marginal Zone Lymphoma Case Reports

6

MZL Epidemiology and Patient Population

6.1

United States

6.2

EU5 Countries

6.2.1

Germany

6.2.2

France

6.2.3

Italy

6.2.4

Spain

6.2.5

United Kingdom

6.3

Japan

7

Current Marginal Zone Lymphoma Treatment and Medical Practices

8

Marginal Zone Lymphoma Unmet Needs

9

Marginal Zone Lymphoma Marketed Drugs

9.1

Revlimid (lenalidomide) in combination with rituximab: Celgene Corporation, Bristol-Myers Squibb

9.2

Imbruvica (ibrutinib): AbbVie, Janssen Biotech

10

Marginal Zone Lymphoma Emerging Drugs

10.1

Key Cross Competition

10.2

Umbralisib (TGR-1202): TG Therapeutics

10.3

Aliqopa (Copanlisib): Bayer

10.4

Ublituximab: TG Therapeutics

10.5

Obinutuzumab: Roche Pharma

10.6

Yescarta (axicabtagene ciloleucel): Gilead Sciences

10.7

Keytruda (Pembrolizumab): Merck Sharp & Dohme

10.8

CLR 131: Cellectar Biosciences

10.9

Parsaclisib: Innovent Biologics

10.10

Nivolumab (Oppdivo): Bristol-Myers Squibb

10.11

Calquence (acalabrutinib): Astrazeneca

10.12

Betalutin (177Lu-satetraxetan-lilotomab): Nordic Nanovector

10.13

Navitoclax (ABT-263): AbbVie

10.14

Orelabrutinib (ICP-022): InnoCare Pharma

10.15

M7583: Merck KGaA

10.16

ARQ 531: ArQule/Merck

10.17

Duvelisib: Verastem/Secura Bio

10.18

Zanubrutinib: BeiGene

10.19

Zandelisib: MEI Pharma

10.20

ALT-803: NantKwest/ImmunityBio

10.21

LOXO-305: Loxo Oncology/Eli Lilly

10.22

SD-101: TriSalus Life Sciences

11

MZL Patient Journey

12

7MM Marginal Zone Lymphoma Market Analysis

13

Potential of MZL Emerging Therapies

14

Key Marginal Zone Lymphoma Market Forecast Assumptions

15

United States MZL Market Outlook

16

EU-5 MZL Market Outlook

16.1

Germany Market Size

16.2

France Market Size

16.3

Italy Market Size

16.4

Spain Market Size

16.5

United Kingdom Market Size

17

Japan MZL Market Outlook

18

Marginal Zone Lymphoma Market Drivers

19

Marginal Zone Lymphoma Market Barriers

20

Reimbursement and Marginal Zone Lymphoma Market Access

21

Recognized Establishments

22

Appendix

23

DelveInsight Capabilities

24

Disclaimer

25

About DelveInsight

Browse detailed TOC with charts, figures, tables @ Marginal Zone Lymphoma Therapeutic Market 

View Related Reports       

DelveInsight's Marginal Zone Lymphoma - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology.

DelveInsight's Morquio Syndrome Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology. 

DelveInsight's Diabetes Market Insights, Epidemiology and Market Forecast - 2030 report provides thorough insights on epidemiology and market trends.

DelveInsight's Buerger's Disease Market Insights, Epidemiology and Market Forecast - 2030 report provides thorough insights on epidemiology and market trends.

DelveInsight's Multiple Sclerosis- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology. 

DelveInsight's Chronic Wounds Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology.

DelveInsight's Smoking Cessation - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.

DelveInsight's Radiation Toxicity Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology. 

DelveInsight's Indolent Lymphoma - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.

DelveInsight's 'ICOS-Next Generation Immunotherapy- Competitive Landscape and Market Forecast–2035' report delivers an in-depth understanding of the ICOS as well as the market trends.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Voltar noticias em Inglês